The global rise in antibiotic resistance threatens infection prevention and cure
21 May 2019
Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic stewardship required to offset this global threat, and the additional incentivisation initiatives needed to promote innovation, as well as the role of preventative antimicrobial treatments as an important element of this global fight against AMR.
Further reading: Pharmafile
Healthy Patients Smart Innovations
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.